Search Result

Results for "

LDLR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (3) LXR (1) NF-κB (1) PPAR (1) Ser/Thr Protease (10) Small Interfering RNA (siRNA) (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (6) Inflammation/Immunology (2) Metabolic Disease (7)

Inhibitors & Agonists

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Targets Recommended: LDLR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS07575

LDLR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LDLR Human Pre-designed siRNA Set A contains three designed siRNAs for LDLR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LDLR Human Pre-designed siRNA Set A LDLR Human Pre-designed siRNA Set A

HY-149310

Dim16	Ser/Thr Protease	Metabolic Disease
Dim16 is a dual PCSK9/HMG-CoAR inhibitor, with an IC₅₀ value of 19 nM for PCSK9. Dim16 inhibits PCSK9-LDLR binding with an IC₅₀ value of 0.8 nM. Dim16 increases LDL uptake in HepG2 cells .

HY-147279

Milpocitide

LDLR Others

Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

Milpocitide	LDLR	Others
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

HY-157434

PCSK9-IN-23	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-23 (compound 5C) is a potent PCSK9 inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .

HY-160036

PCSK9-IN-22	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo .

HY-155415

PCSK9-IN-20	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC₅₀ of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .

HY-152221

PCSK9-IN-10	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

HY-P9930

Evolocumab 1 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-132897

PCSK9-IN-2

Ser/Thr Protease Cardiovascular Disease

PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC₅₀ value of 7.57 μM.

PCSK9-IN-2	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-2 is a novel small molecule inhibitor of *PCSK9-LDLR* protein–protein interaction (PPI) with an IC₅₀ value of 7.57 μM.

HY-125544

LY 295427 Agisterol	LDLR	Metabolic Disease
LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .

HY-P99626

Frovocimab LY 3015014	Ser/Thr Protease	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-101529

Imanixil HOE-402(free base)	LDLR	Cardiovascular Disease
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .

HY-149429

PPARδ agonist 9	PPAR	Metabolic Disease
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC₅₀: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .

HY-141714

SBC-115337

Ser/Thr Protease Cancer

SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC₅₀ value of 0.5 μM .

SBC-115337	Ser/Thr Protease	Cancer
SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC₅₀ value of 0.5 μM .

HY-152223

PCSK9-IN-11	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC₅₀ of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .

HY-152262

LXRβ agonist-4	LXR	Inflammation/Immunology
LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC₅₀ value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .

Cat. No.	Product Name	Target	Research Area

HY-P9930

Evolocumab 1 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P99626

Frovocimab LY 3015014	Ser/Thr Protease	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

Species:	Human (4) Mouse (2) Cynomolgus (1)
Tag:	His (7) Avi (2)
Source:	HEK293 (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P70235

	LDLR Protein, Human (HEK293, His) 1 Publications Verification rHuLow-density lipoprotein receptor/LDLR, His; Low-Density Lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of LDLR Protein, Human (HEK293, His) is 767 a.a., with molecular weight of 99-135 kDa.

HY-P73272

	LDLR Protein, Mouse (HEK293, His) Low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Mouse (HEK293, His) is 769 a.a., with molecular weight of ~98-130 kDa.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) Low-Density Lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is 767 a.a., with molecular weight of 95-140 kDa.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) Low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation. The total length of LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is 790 a.a., with molecular weight of ~85.7 kDa.

HY-P77735

	LDLR Protein, Cynomolgus (HEK293, His) LDLR; FHC; LDL R; LDL receptor; LDLCQ2; FH	Cynomolgus	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Cynomolgus (HEK293, His) is 767 a.a., with molecular weight of 115-130 kDa.

HY-P700860

	LDLR Protein, Human (HEK293, Avi-His) LDLR; FHC; LDL R; LDL receptor; LDLCQ2; FH	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of LDLR Protein, Human (HEK293, Avi-His) is 767 a.a., with molecular weight of 110-130 kDa.

HY-P76492

	MESDC2 Protein, Human (HEK293, His) LRP chaperone MESD; LDLR chaperone MESD; KIAA0081; MESDM	Human	HEK293
	The MESDC2 protein acts as a chaperone and plays a specific role in promoting the folding of the β-propeller/EGF module within the low-density lipoprotein receptor (LDLR) family. In addition to participating in LDLR folding, MESDC2 acts as an important regulator of the Wnt pathway by chaperoning the coreceptors LRP5 and LRP6 to the plasma membrane, thereby affecting Wnt signaling. MESDC2 Protein, Human (HEK293, His) is the recombinant human-derived MESDC2 protein, expressed by HEK293 , with C-His labeled tag. The total length of MESDC2 Protein, Human (HEK293, His) is 197 a.a., with molecular weight of ~27 KDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P81109

LDLR Antibody LDLR_HUMAN; Low-density lipoprotein receptor; LDL receptor; FH; FHC; FHCL1; LDLCQ2; low density lipoprotein receptor	WB; ELISA; Flow-Cyt; ICC	Human, Mouse(predicted: Rat, Dog, Pig, Cow, Horse, Rabbit, Guinea Pig)
LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR polyclonal antibody. LDLR Antibody can be used for: WB, ELISA, Flow-Cyt, ICC expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, rabbit, guinea pig background without labeling.

HY-P82565

SorLA Antibody (YA2310) SORL1; C11orf32; Sortilin-related receptor; Low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P	Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.